ArticleFrontiers in bioengineering and biotechnology2025
Ultrasound-responsive phase-transitional nanomedicine enables intensity-tunable postoperative analgesia.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Nanoscale Drug Delivery Systems for Pain.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Effective handling of pain after surgery is a major clinical issue, since insufficient pain relief is associated with extended recovery, excessive opioid use, and increased healthcare. Current approaches are limited by the short duration of local anesthetics, opioid-related adverse effects, and the lack of dynamic adjustability in pain relief. Here we report a theranostic nanoplatform, Rg3-liposomes@DMSN-levobupivacaine-PFP (RDLP), which integrates ultrasound-triggered phase transition, contrast-enhanced ultrasound (CEUS) imaging, and intensity-tunable drug release to address these limitations. Methods: RDLP features a core-shell architecture: dendritic mesoporous silica nanoparticles (DMSN) encapsulate the local anesthetic levobupivacaine and the phase-transition agent perfluoropentane (PFP), with a biocompatible Rg3-liposome coating enhancing stability and reducing drug leakage. Upon ultrasound irradiation, PFP undergoes liquid-to-gas phase transition, generating microbubbles that amplify CEUS signals for real-time visualization of drug distribution and drive inertial cavitation to trigger burst release of levobupivacaine. This design achieves high levobupivacaine encapsulation efficiency and enables spatiotemporally controlled release, with ultrasound accelerating drug release kinetics Results: RDLP combined with ultrasound prolonged analgesia compared to free levobupivacaine and enabled on-demand adjustment of pain relief intensity via multiple ultrasound irradiation cycles, restoring paw withdrawal thresholds and latencies to near-baseline levels Discussion: RDLP bridges imaging guidance and therapeutic intervention, leveraging ultrasound's deep tissue penetration and Rg3's natural biocompatibility to overcome limitations of conventional nerve blocks and ultrasound-responsive systems. This non-invasive, adjustable strategy offering potential to reduce opioid reliance and improve patient outcomes in perioperative care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.